Nicolas M.
- Country
- France
- Department
- Nephrology
Research Overview
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
- Evaluation of Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sibeprenlimab in Patients with Immunoglobulin A Nephropathy
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Povetacicept in Adults with Immunoglobulin A Nephropathy
Data & Insights
Has run more than one trial at 59 of 172 partner sites.
Specializations
Nephrology Focus
Specializes in the investigation of Immunoglobulin A Nephropathy (IgAN), conducting extensive research into innovative therapeutic approaches for this kidney condition.
- Novel Biological Therapies
- Targeted Immunological Treatments
- Proteinuria Management
Investigates various therapeutic agents including sibeprenlimab, atrasentan, and ravulizumab for IgAN treatment.
Renal Disease Management
Focuses on preserving kidney function through investigation of complement pathway inhibitors and evaluation of treatments for hypertensive emergency-associated hemolytic uremic syndrome.
- Renal Function Preservation
- Complement-Mediated Diseases
- Emergency Renal Conditions
Studies interventions for severe kidney involvement requiring dialysis and chronic kidney disease progression.
Therapeutic Innovation
Explores multiple therapeutic modalities including conventional immunosuppressants and novel biological agents for kidney diseases.
- Antimalarial Applications
- B-cell Targeting Therapies
- Standard of Care Enhancement
Evaluates hydroxychloroquine and atacicept among other innovative treatment approaches for nephropathy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.